A Phase 4 interventional study of Maxidex and No treatment in Sjogren's Syndrome, sponsored by Alcon Research. Completed at 2 sites in Canada. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-12.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Sjogren's Syndrome with a site in Canada — 4 open to participants now, 9 under way, 7 of them phase 3. Sjogren's Syndrome · Canada.
Among the 18 studies in Sjogren's Syndrome with a site in Canada, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2008, is the only one in phase 4, and was the 1st registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →4 of the 18 studies in Sjogren's Syndrome with a site in Canada are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 17 more countries
Ages 18+
Amgen · Sites in Canada, United States, Argentina and 23 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 17 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 389 across the 16 interventional studies, 37 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Alcon has 3 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Sjogren's Syndrome with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Sjogren's Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
Inclusion Criteria of Sjorgren's Population:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maxidex
Drug: Maxidex
Healthy normal control group receiving no treatment
Other: No treatment
Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
Healthy normal control group receiving no treatment
Change in Levels of Biomarkers After Dosing With Maxidex
Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.
Time frame: Baseline to 2 weeks
Correlation Between Biomarker Expression and Ocular Symptoms
Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).
Time frame: Baseline to 2 weeks
Correlation Between Biomarker Expression and Tear Film Break up Time
Correlation factor: TNFmRNA vs. TFBUT (Tear Film Break-up Time)
Time frame: Baseline to 2 weeks
Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining
Correlation factor: TNFmRNA vs. NaFl staining
Time frame: Baseline to 2 weeks
Correlation Between Biomarker Expression and the Schirmer Test
Correlation factor: TNFmRNA vs. Schirmer
Time frame: Baseline to 2 weeks
Patients were recruited via flyers, newspaper advertisements, radio advertisements and chart review in the doctors' office.
| Milestone | Maxidex | No Treatment |
|---|---|---|
| Started | 50 | 47 |
| Completed | 44 | 45 |
| Not completed | 6 | 2 |
Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.
| ddCt (Delta-Delta-Ct) | Maxidex | No Treatment |
|---|---|---|
| Baseline | -1.244 ± 1.08 | -0.29 ± 0.88 |
| 2 weeks | -0.033 ± 1.06 | -0.33 ± 0.85 |
Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).
| Correlation factor | Maxidex | No Treatment |
|---|---|---|
| Correlation Between Biomarker Expression and Ocular Symptoms | -0.09 | -0.10 |
Correlation factor: TNFmRNA vs. TFBUT (Tear Film Break-up Time)
| Correlation factor | Maxidex | No Treatment |
|---|---|---|
| Correlation Between Biomarker Expression and Tear Film Break up Time | -0.16 | 0.12 |
Correlation factor: TNFmRNA vs. NaFl staining
| Correlation factor | Maxidex | No Treatment |
|---|---|---|
| Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining | -0.05 | — |
Correlation factor: TNFmRNA vs. Schirmer
| Correlation Factor | Maxidex | No Treatment |
|---|---|---|
| Correlation Between Biomarker Expression and the Schirmer Test | -0.02 | 0.07 |
Collected over Adverse reporting began once the patient enrolled into the study and went on for the duration of the study (6 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maxidex | — | 0/50 (0%) | 0/50 (0%) |
| No Treatment | — | 0/47 (0%) | 0/47 (0%) |
| Age, Categorical(Participants) | Maxidex | No Treatment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 41 | 76 |
| >=65 years | 15 | 6 | 21 |
| Sex: Female, Male(Participants) | Maxidex | No Treatment | Total |
|---|---|---|---|
| Female | 48 | 43 | 91 |
| Male | 2 | 4 | 6 |
The record gives a start of Feb 2008 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone